Evidence map›Paper›PMID 26311690›Full record

ArticleNeuro-oncology2016

Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.

Ka-Loh Li, Ibrahim Djoukhadar, Xiaoping Zhu, Sha Zhao, Simon Lloyd, Martin McCabe, Catherine McBain, D Gareth Evans, Alan Jackson

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  5. Efficacy and safety of bevacizumab for vestibular schwannomas in neurofibromatosis type-2: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.Journal of neurological surgery. Part B, Skull base · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ka-Loh LiWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Ibrahim DjoukhadarWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Xiaoping ZhuWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Sha ZhaoWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Simon LloydWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Martin McCabeWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Catherine McBainWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
D Gareth EvansWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Alan JacksonWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UK (K.-L.L., I.D., X.Z., S.Z., A.J.); Institute of Population Health, The University of Manchester, Manchester, UK (K.-L.L., I.D., A.J.); Genomic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK (S.L., D.G.E.); Centre for Paediatric, Adolescent and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, UK (M.M.); The Christie NHS Foundation Trust, Manchester, UK (C.M.).
Cancer Research UK Manchester Institute · GBManchester Academic Health Science Centre · GBThe Christie NHS Foundation Trust · GBUniversity of Manchester · GBManchester Royal Infirmary · GB

Funding

Cancer Research UK 16465Cancer Research UK 18097Cancer Research UK C8742/A18097
6 · The paper itself

Abstract

backgroundAntiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting.

methodsTwelve patients with 20 VSs were recruited. Each had at least one rapidly growing tumor. Patients were treated with bevacizumab, 5 mg/kg every 2 weeks. Patients with stable or reduced VS volume were maintained at 2.5-5 mg every 4 weeks after 6 months. Those who failed treatment had their bevacizumab discontinued. Dynamic contrast-enhanced (DCE) MRI performed prior to treatment using a high temporal resolution technique, and data were analyzed to allow measurement of contrast transfer coefficient (K(trans)), vascular fraction (v(p)), extravascular-extracellular fraction (v(e)). Relaxation rate (R1(N)) was measured using a variable flip angle technique. Apparent diffusional coefficient (ADC) was calculated from diffusion-weighted imaging. The predictive power of microvascular parameters and ADC were examined using logistic regression modeling.

resultsResponding tumors were larger (P < .001), had lower R1(N) (P < .001), and higher K(trans) (P < .05) and ADC (P < .01). They showed increases in R1(N) (P < .01) and reduction of K(trans) (P < .01) and ADC (P < .01). Modeling to predict response demonstrated significant independent predictive power for R1(N) (Β = - 0.327, P < .001), and K(trans) (Β = 0.156, P < .05). Modeling to predict percentage change in tumor volume at 90 days identified baseline tumor volume (Β = 5.503, P < .05), R1(N) (Β = - 5.844, P < .05), and K(trans) (Β = 5.622, P < .05) as independent significant predictors.

conclusionsIn patients with type 2 neurofibromatosis, biomarkers from DCE-MRI are predictive of VS volume response to inhibition of vascular endothelial growth factor inhibition.

Indexed as

Contrast MediaAdolescentAdultAngiogenesis InhibitorsBevacizumabBiomarkers, TumorFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeurofibromatosis 2Neuroma, AcousticAngiogenesis InhibitorsBevacizumabBiomarkers, TumorContrast MediaVascular Endothelial Growth Factor AVEGFA protein, humanbevacizumabDCE-MRIneurofibromatosis type 2predictiontreatment response

Identifiers

PMID26311690
PMCPMC4724182
OpenAlexW2218004332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.